Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients

Chest

Volumn 113, Issue 5, 1998, Pages 1178-1183

  Kimerling, Michael E ^a,b,d   Phillips, Penny ^b   Patterson, Patricia ^b   Hall, Marilyn ^c   Robinson, C Andrew ^c   Dunlap, Nancy E ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Drug monitoring; Intestinal absorption; Tuberculosis

Indexed keywords

ANTIMYCOBACTERIAL AGENT; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTESTINE ABSORPTION; MALE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; TREATMENT FAILURE; TUBERCULOSIS; TUBERCULOSIS CONTROL; VENOUS BLOOD;

EID: 0031901988     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.113.5.1178     Document Type: Article

References (17)

1. Berning SE, Huitt GA, Isema MD, et al. Malabsorption of antituberculosis medications by a patient with AIDS [letter]. N Engl J Med 1992; 327:1817-18
2. Peloquin CA, MacPhee AA, Berning SE. Malabsorption of antimycobacterial medications [letter]. N Engl J Med 1993; 329:1122-23
3. Gordon SM, Horsburgh CR, Peloquin CA, et al. Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease. J Infect Dis 1993; 168:1559-62
4. Patel KB, Belmonte R, Crowe HM. Drug malabsorption and resistant tuberculosis in HIV infected patients [letter]. N Engl J Med 1995; 332:336-37
5. Holdiness MR. Clinical pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet 1984; 9:511-44
6. Peloquin CA. Therapeutic drug monitoring: principles and application in mycobacterial infections. Drug Ther 1992; 22:31-36
7. Peloquin CA. Pharmacology of the antimycobacterial drugs. Med Clin North Am 1993; 77:1253-62
8. Gaitonde CD, Pathak PV. Rapid liquid chromatographic method for the estimation of isoniazid and pyrazinamide in plasma and urine. J Chromatogr B Biomed Appl 1990; 532:418-23
9. El-Yazigi A, Raines DA. Simultaneous microdetermination of rifampin, deacetylrifampin, isoniazid, and acetylisoniazid in plasma by liquid chromatography with dual electrochemical and spectrophotometric detection. Pharm Res 1992; 9:812-16
10. Conover WJ. Practical nonparametric statistics. 2nd ed. New York: John Wiley, 1980
11. Weber WW, Hein DW. Clinical pharmacokinetics of isoniazid. Clin Pharmacokinet 1979; 4:401-22
12. Buniva G, Pagani V, Carozzi A. Bioavailability of rifampicin capsules. Int J Clin Pharmacol Ther Toxicol 1983; 21:404-09
13. Notterman DA, Nardi M, Saslow JG. Effect of dose formulation on isoniazid absorption in two young children. Pediatrics 1986; 77:850-52
14. Borcherding SM, Baciewicz AM, Self TH. Update on rifampin drug interactions II. Arch Intern Med 1992; 152: 711-16
15. Cavenaghi R. Rifampicin raw material characteristics and their effect on bioavailability. Bull Int Union Tubere Lung Dis 1989; 64:36-37
16. Acocella G. Human bioavailability studies. Bull Int Union Tubere Lung Dis 1989; 64:38-41.
17. Sbarbaro JA. A challenge - to our practices and to our principles. Tuber Lung Dis 1996; 77:2-3